The content on this site is intended for healthcare professionals only
Dr Churchman speaks with ecancertv at ASH 2016 about the mutations in IKZF1, or Ikaros, that are associated with worse outcomes for childhood leukaemia.
She outlines a suite of heritable mutations which result in a stem-like behaviour, cell adhesion and drug resistance within the bone marrow.
Dr Churchman explains how next generation sequencing could help in identifying patients most suited to targeted therapy.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Revolutionising myeloma treatment through immune profiling
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
